Beovu safety issues were a dominant topic at a recent national meeting of eye doctors. They discussed possible Beovu side effects such as occlusive vasculitis and vision loss following Beovu injections for treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD).
We get these significant points from this July 26, 2020, Ocular Surgery News article, “ASRS, Novartis independent committees review safety, risks of Beovu”:
The Novartis safety review committee identified a rate of 4.6% of [intraocular inflammation (IOI)] of all types.
“Of that, there was a subgroup of patients who developed occlusive vasculitis, in 2.1% of patients,” [said Paul Hahn, MD, PhD, who moderated a panel on drug safety at the July 2020 annual meeting for American Society of Retina Specialists].
In terms of risk, 1 in 200 represents the overall risk of any patient beginning [Beovu (brolucizumab)] therapy losing six or more lines of vision due to occlusive vasculitis.
“Alternatively, if you have a patient who presents to your office having occlusive vasculitis following recent Beovu, that patient has a 1 in 5 risk of at least six-line vision loss,” Hahn said.
We have been closely following developments concerning Beovu safety issues for several months now, and we will continue to watch for developments concerning possible Beovu side effects in the regulatory, medical, and legal realms.
Our law firm has heard from individual patients about cases of Beovu injections causing vision loss and blindness due to occlusive retinal vasculitis, retinal artery occlusion, and intraocular inflammation. These cases are being investigated as potential drug injury lawsuits against Novartis Pharmaceuticals Corporation, the drug company responsible for Beovu here in the US.[View article at original source]